Edwards Lifesciences Corporatio (EW) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. At $81.38, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%).
Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter Mitral and Tricuspid Therapies (9%), and Surgical heart valves (17%). In 2025, 58% of net sales came from U.S. customers; no single customer exceeded 10% of revenues.
Sell if holding. At $81.38, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 67d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Edwards Lifesciences Corporatio
Material events (past 30 days)
- May 4, 2026 MEDIUM Item 5.02: Edwards Lifesciences appointed Theodora Mistras as Corporate VP and CFO effective May 29, 2026, to succeed Scott B. Ullem. Mistras previously served as CFO of Viatris, Inc. No reason cited for Ullem's departure.
Latest news
- EW (Edwards Lifesciences Corporation) reports Q4 2025 EPS miss, shares climb 2.45 percent amid positive investor sentime — Cổng thông tin điện tử Tỉnh Sơn La negative
- Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,165 Shares of Edwards Lifesciences Corporation $EW - Mark — MarketBeat neutral
- EW DCF Analysis: Intrinsic Value $48 vs Price $78 - GuruFocus — GuruFocus negative
- Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Zurcher Kantonalbank Zurich Cantonalbank Buys 23,305 Shares of Edwards Lifesciences Corporation $EW - MarketBeat — MarketBeat positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductTAVR74%10-K Item 1: 'Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.'
- HIGHGeographicUnited States58%10-K Item 1: 'In 2025, 58% of our net sales were derived from sales to customers in the United States.'
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMEdwards Lifesciences appointed Theodora Mistras as Corporate VP and CFO effective May 29, 2026, to succeed Scott B. Ullem. Mistras previously served as CFO of Viatris, Inc. No reason cited for Ullem's departure.SEC filing →
- 2026-05-08Item 5.02LOWAt the 2026 Annual Meeting on May 7, 2026, stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program, increasing authorized shares by 7 million to 341.5 million total. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $81.38, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $76.24. Score 5.3/10, moderate confidence.
Take-profit target: $87.43 (+7.4% upside). Prior stop was $76.24. Stop-loss: $76.24.
Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%); Thin upside margin: 7.4%.
Edwards Lifesciences Corporatio trades at a P/E of 44.0 (forward 24.2). TrendMatrix value score: 4.2/10. Verdict: Sell.
43 analysts cover EW with a consensus score of 4.0/5. Average price target: $97.
What does Edwards Lifesciences Corporatio do?Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter...
Edwards Lifesciences develops structural heart technologies including TAVR (74% of 2025 net sales), Transcatheter Mitral and Tricuspid Therapies (9%), and Surgical heart valves (17%). In 2025, 58% of net sales came from U.S. customers; no single customer exceeded 10% of revenues.